Stock Track | Arcutis Biotherapeutics Soars 5.15% Intraday on Strong Earnings and Analyst Upgrades

Stock Track

02/27

Arcutis Biotherapeutics Inc. (ARQT) saw its stock price soar 5.15% during intraday trading on Thursday.

The significant price movement follows the company's release of strong fourth quarter and full year 2025 financial results. Arcutis reported a swing to profitability with Q4 earnings exceeding analyst estimates, while revenue for the quarter showed an 81.5% year-over-year increase driven by robust demand for its ZORYVE product. The company also raised its full-year 2026 net product revenue guidance.

The positive earnings report prompted multiple analyst firms to raise their price targets on the stock, contributing to the bullish sentiment. Morgan Stanley increased its target to $35 from $32, TD Cowen raised its target to $35 from $30, and H.C. Wainwright lifted its target to $34 from $30, with several firms maintaining their Buy ratings.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1124636542"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1124636542\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1124636542?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 04:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124636542","market":"us","top_or_hot":-1,"title":"Stock Track | Arcutis Biotherapeutics Soars 5.15% Intraday on Strong Earnings and Analyst Upgrades","media":"Stock Track","content":"<p>Arcutis Biotherapeutics Inc. (ARQT) saw its stock price soar 5.15% during intraday trading on Thursday.</p><p>The significant price movement follows the company's release of strong fourth quarter and full year 2025 financial results. Arcutis reported a swing to profitability with Q4 earnings exceeding analyst estimates, while revenue for the quarter showed an 81.5% year-over-year increase driven by robust demand for its ZORYVE product. The company also raised its full-year 2026 net product revenue guidance.</p><p>The positive earnings report prompted multiple analyst firms to raise their price targets on the stock, contributing to the bullish sentiment. Morgan Stanley increased its target to $35 from $32, TD Cowen raised its target to $35 from $30, and H.C. Wainwright lifted its target to $34 from $30, with several firms maintaining their Buy ratings.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Arcutis Biotherapeutics Soars 5.15% Intraday on Strong Earnings and Analyst Upgrades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Arcutis Biotherapeutics Soars 5.15% Intraday on Strong Earnings and Analyst Upgrades\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-02-27 04:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Arcutis Biotherapeutics Inc. (ARQT) saw its stock price soar 5.15% during intraday trading on Thursday.</p><p>The significant price movement follows the company's release of strong fourth quarter and full year 2025 financial results. Arcutis reported a swing to profitability with Q4 earnings exceeding analyst estimates, while revenue for the quarter showed an 81.5% year-over-year increase driven by robust demand for its ZORYVE product. The company also raised its full-year 2026 net product revenue guidance.</p><p>The positive earnings report prompted multiple analyst firms to raise their price targets on the stock, contributing to the bullish sentiment. Morgan Stanley increased its target to $35 from $32, TD Cowen raised its target to $35 from $30, and H.C. Wainwright lifted its target to $34 from $30, with several firms maintaining their Buy ratings.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARQT","symbol_name":"Arcutis Biotherapeutics Inc.","start_time":0,"source_url":"","article_id":"1124636542","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124636542","pubTimestamp":1772137859,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Arcutis Biotherapeutics Inc. (ARQT) saw its stock price soar 5.15% during intraday trading on Thursday.The significant price movement follows the company's release of strong fourth quarter and full...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARQT":"Arcutis Biotherapeutics Inc."},"translate_title":"个股追踪|Arcutis Biotherapeutics盘中大涨5.15%因强劲盈利和分析师上调评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARQT":1},"content_text":"Arcutis Biotherapeutics Inc. (ARQT) saw its stock price soar 5.15% during intraday trading on Thursday.The significant price movement follows the company's release of strong fourth quarter and full year 2025 financial results. Arcutis reported a swing to profitability with Q4 earnings exceeding analyst estimates, while revenue for the quarter showed an 81.5% year-over-year increase driven by robust demand for its ZORYVE product. The company also raised its full-year 2026 net product revenue guidance.The positive earnings report prompted multiple analyst firms to raise their price targets on the stock, contributing to the bullish sentiment. Morgan Stanley increased its target to $35 from $32, TD Cowen raised its target to $35 from $30, and H.C. Wainwright lifted its target to $34 from $30, with several firms maintaining their Buy ratings.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}